View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 2, 2020

Gates Foundation’s Covid-19 accelerator makes first investments

By Allie Nawrat

The Bill & Melinda Gates Foundation, Wellcome and Mastercard’s Covid-19 Therapeutics Accelerator, which was launched in mid-March with $125m, has made its first investments into three institutions to support immunotherapy research.

The institutions in question are the University of Washington, University of Oxford, and La Jolla Institute for Immunology, and they have received a total combined funding of $20m.

The University of Washington and University of Oxford are both working on trials of anti-malarials chloroquine and hydroxychloroquine in Covid-19 patients, which will be supported by this new funding. Whereas La Jolla will use its $1.73 investment to establish a consortium to share candidate antibodies with researchers across the world.

The Bill & Melinda Gates Foundation CEO Mark Suzman explained: “These grants to leading institutions in their fields will advance our understanding of how existing drugs and antibodies can contribute to addressing the pandemic we’re facing around the world.

“These initial investments through the Covid-19 Therapeutics Accelerator will bring rigour to the study of these potential solutions. The way forward will be informed by sound science and shared data.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU